Assessment of nonhematologic toxicity and worst grade per patient
| Toxicity . | Grade . | |
|---|---|---|
| All grades . | Grades 3/4 . | |
| Bacterial pneumonia∗ | 8 | 1 |
| Constipation | 18 | 0 |
| COVID-19† | 5 | 1 |
| Cushing syndrome | 2 | 0 |
| Dizziness | 9 | 0 |
| Fatigue/asthenia | 11 | 0 |
| Febrile neutropenia during ASCT‡ | 21 | 21 |
| Herpes zoster virus | 3 | 1 |
| Hyperglycemia | 17 | 0 |
| Hypertension | 5 | 4 |
| Infusion reaction | 9 | 2 |
| Insomnia | 7 | 0 |
| Joint pain | 8 | 0 |
| Muscle pain | 9 | 0 |
| Nausea | 13 | 1 |
| Peripheral edema | 14 | 1 |
| Peripheral neuropathy | 23 | 1 |
| Pruritus | 11 | 0 |
| Skin rash | 13 | 1 |
| Somnolence | 2 | 0 |
| Stomatitis during ASCT | 21 | 6 |
| Syncope | 5 | 3 |
| Tremors | 9 | 1 |
| Upper respiratory tract infection | 19 | 0 |
| Venous thrombosis | 1 | 0 |
| Toxicity . | Grade . | |
|---|---|---|
| All grades . | Grades 3/4 . | |
| Bacterial pneumonia∗ | 8 | 1 |
| Constipation | 18 | 0 |
| COVID-19† | 5 | 1 |
| Cushing syndrome | 2 | 0 |
| Dizziness | 9 | 0 |
| Fatigue/asthenia | 11 | 0 |
| Febrile neutropenia during ASCT‡ | 21 | 21 |
| Herpes zoster virus | 3 | 1 |
| Hyperglycemia | 17 | 0 |
| Hypertension | 5 | 4 |
| Infusion reaction | 9 | 2 |
| Insomnia | 7 | 0 |
| Joint pain | 8 | 0 |
| Muscle pain | 9 | 0 |
| Nausea | 13 | 1 |
| Peripheral edema | 14 | 1 |
| Peripheral neuropathy | 23 | 1 |
| Pruritus | 11 | 0 |
| Skin rash | 13 | 1 |
| Somnolence | 2 | 0 |
| Stomatitis during ASCT | 21 | 6 |
| Syncope | 5 | 3 |
| Tremors | 9 | 1 |
| Upper respiratory tract infection | 19 | 0 |
| Venous thrombosis | 1 | 0 |